Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Proteome Sciences Plc LSE:PRM London Ordinary Share GB0003104196 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 5.01 129,537 08:00:12
Bid Price Offer Price High Price Low Price Open Price
4.54 5.45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 4.66 -0.04 0.05 100.2 15
Last Trade Time Trade Type Trade Size Trade Price Currency
08:25:50 O 14,076 4.904 GBX

Proteome Sciences (PRM) Latest News

More Proteome Sciences News
Proteome Sciences Investors    Proteome Sciences Takeover Rumours

Proteome Sciences (PRM) Discussions and Chat

Proteome Sciences Forums and Chat

Date Time Title Posts
14/4/202108:24Proteome, what next? (moderated)58,889
07/4/202112:39Proteome Sciences leading Alzheimer's technology.88,794
13/5/202019:36Only worth 3p on fundamentals....10
28/4/202007:22Proteome Sciences plc, A Three Horse Race for the Month of May.4,854
02/7/201917:54The useful PRM thread13

Add a New Thread

Proteome Sciences (PRM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:25:514.9014,076690.29O
07:05:164.9073,8833,623.22O
07:02:575.2840,7382,150.97O
07:00:124.541004.54O
07:00:124.5474033.60O
View all Proteome Sciences trades in real-time

Proteome Sciences (PRM) Top Chat Posts

DateSubject
14/4/2021
09:20
Proteome Sciences Daily Update: Proteome Sciences Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PRM. The last closing price for Proteome Sciences was 5.01p.
Proteome Sciences Plc has a 4 week average price of 3.54p and a 12 week average price of 3.52p.
The 1 year high share price is 7p while the 1 year low share price is currently 3.02p.
There are currently 294,648,723 shares in issue and the average daily traded volume is 811,673 shares. The market capitalisation of Proteome Sciences Plc is £14,761,901.02.
01/4/2021
14:54
stocktastic: "You seemed to think it was perfectly OK for a public company to have insufficient control or understanding of its finances that within 2 months of a year-end trading update it is talking about "material" differences to sums received. " Jeffian, you were trying to suggest my understanding of financial accounting was mistaken, but now backtrack and fail to show what was wrong. Now, re the above, I get where you are coming from, but you are missing how things work in the real world 1. PRM does not control the royalties, end of. How can you therefore sensibly expect them to have more control of this part of the finances. Makes no sense. PRM could control timing only - and they had to revise upwards - so what 2. PRM was working off £30k profits. A small change in the high margin royalties would shift that materially.. albeit still only a small change in absolute terms. There is no suggestion at all of PRM not understanding its finances So, your and Golly's mocking remarks in fact only highlighted your own failed understanding and I'd bet, absence of real world experience of working with accruals
26/3/2021
15:46
stocktastic: "What you are all missing is why was there an rise in TMT in the last quarter" It has a trend of more, but came in higher than PRM expected - less COV impact vs what PRM assumed? - higher volume uses kicking in? - PRM being misleading with wording?
26/3/2021
13:14
bluemango: Excuse me, I seem to have inadvertently stepped into a time machine back to 2003 (apart from the PRM share price which remains stubbornly low). There must be a door somewhere in this thing, hang on.
16/3/2021
08:49
stocktastic: .... just to avoid any confusion, my last post was in jest - I have not bought any PRM Fwiw though, I can see industry tailwinds helping PRM as described, so who knows (all we do know is PRM has long struggled and the new CEO has shown no external signs of doing much at all to change that)
05/3/2021
12:45
elpirata: I suspect monte1 might have peeked at the share price which corresponds with the value the market places on prm and your calculation 1xtrader?
18/2/2021
12:43
stocktastic: Thermo makes money off TMT, paying PRM a royalty and amounts for bulk product. Buying PRM would make sense if the value of these future TMT payments materially exceeded the market cap plus debt... and PRM agreed It probably does. PRM would be a clearly profitable business if it didnt spend so much on admin staff that add insufficient value
22/1/2021
07:46
stocktastic: Back to PRM Our Leaders Executive Team Dr. Mariola Söhngen - Chief Executive Officer and Executive Director Dr. Mariola Söhngen Mariola Söhngen has established a strong and successful career in the pharmaceutical industry both in the US and Europe. She was a co-founder of Paion AG which developed a clinical-stage asset for the treatment of stroke and subsequently delivered a novel anaesthetic that received FDA approval in 2020. Mariola Söhngen was instrumental in the acquisition of UK listed CeNeS Pharmaceuticals plc by Paion AG. Mariola Söhngen has also held roles as CEO at Mologen AG and Convert Pharmaceuticals and most recently ran a pharmaceutical consultancy with a strong focus on supporting Chinese companies and investors trying to enter the European pharmaceuticals research and development market. In Mariola Söhngen's first four months at PRM, she steered the company without one single press release or externslly visible move, leaving investors wondering if she had done anything at all (Last sentence added, if not clear) Maybe a sweepstake on when she will announce something? My guess is next week. Going beyond end Jan is just strange. Maybe she feels she is doing a thorough review? I say slow In terms of content, I expect excuses regarding COVID of course. Likely mention of her doing a (slow) strategic review ...but imo probably nothing of note in terms of her actually doing anything of value with the core business, because I dont see mucb more they csn do, hence CEO role being a waste of money. Longer term, I do think she will try a merger. You never know... if started by Haigh, we might hear of that sooner. Vulpes pushing up the share price would help a share based transaction
16/11/2020
13:13
tom barnaby: The Gulpster - 11 Sep'08 - 16:19 - 40270 of 40293 Peter Snodgrass - 13 Mar'06 - I think you will find, on the basis that the deal was finally agreed between all the parties on 19 Feb, that the trading on 20th (partly - perhaps mainly?- from US) indicated that the rumours had become quite widespread. Peter Snodgrass - 13 Mar'06 - ....on the basis that the deal was finally agreed between all the parties on 19 Feb, that the trading on 20th (partly - perhaps mainly?- from US) indicated that the rumours had become quite widespread....It is the delay in the announcement of signing that has allowed the shorters to cause the price to drift since. But I believe that the deal has effectively been done, and that the delay in announcing it has been due solely to the US procedures that have to be completed first.... Peter Snodgrass - 23 Oct'06 - ....Probable sequence of events....announcement of any deals (TMT?) that make PRM profitable will be followed by:- (a). A sharp rise in the share price augmented by shorters closing. (b) An announcement of the link up with GE. (An even bigger rise?) (c) A statement of all the developments – at least regarding commercialisation – that have resulted from the collaboration with Amersham / GE Healthcare during the last three years. (Yet a further rise.) OR - ? – AND THEN (d) HOPEFULLY. GE making a substantial injection of funds, at a premium to the present price (like Aventis did) to take a major stake in PRM and also announces JVs for oncology etc. and the probably already agreed (?) licences for Alzheimer’s, partnership for TMT, etc. This could include GE acquiring the 18m shares from Sanofi/Aventis. (e) PROBABLY. GE offers a partnership (as recently with another company) based on either a current valuation or on a multiple of an average share price. (f) POSSIBLY. GE making a takeover bid at an agreed price – based on valuation but perhaps (like with the Swedish biotech company) a multiple of the average share price. (g) ALTERNATIVELY. A series of JVs for various parts of PRM’s IP. I cannot foresee any other options. The only question is WHEN? But the rumours of “during the next four weeks” are the strongest I have ever heard. Peter Snodgrass - 20 Nov'07 - We all, I think, expected the announcement of the TMT deal last Tuesday - and those that had followed my takeover theory expected the takeover bid to follow. Peter Snodgrass - 21 Nov'07 - ...I suggested, based on similar previous events, that it should not take more than a week. so I would not be surprised to see the announcements even today or tomorrow....But if is not by tomorrow morning, then the US holiday would probably delay them until next Tuesday.....Assuming....my GE theory is correct (ie IMO/DYOR) - what investors do not seem to realise is the enormous, and instant, impact these unexpected announcements seem likely to have on the share price - all of the last four years of progress and the true value of PRM's IP being publicised in one BIG BANG! Peter Snodgrass - 23 Nov'07 - "today/Monday morning" fits in with rumours I have heard that PRM are working very hard indeed to get the BIG announcements out without further delay goatherd - 10 Dec'07 - .....Several people have suggested TMT alone should take the price to 80 to 100p. Peter Snodgrass, who has a theory which explains much of what has happened over the years, believes a minimum price of £5 is likely after a flurry of news around the time of the TMT news..... Peter Snodgrass - 19 Dec'07 - ....Amersham is now part of GE Healthcare so it is GE who hold the 50% TMT....the estimate value of £12 per share has also reached me from two other (reliable) sources. Peter Snodgrass - 27 Dec'07 - ....CEO is reported to have said that the value within PRM is such that the share price should be over £12......done my homework VERY thoroughly over the last 12 years I agree with him Peter Snodgrass - 27 Dec'07 - .....I do not consider a share price exceeding £8 to be impossible by the end of January.... Peter Snodgrass - 28 Dec'07 - IMO/DYOR I am going to suggest that anyone investing in PRM at this price level cannot fail to see a huge profit within a few weeks and perhaps only days......Furthermore, those who have acted on my suggestion and bought (at whatever price and whenever) AND HELD ON are shortly going to be rewarded with a very handsome profit on their original investment.....we have a clear indication of the time scale relating to the news that will transform PRM and reveal its true value......investors who take advantage of this “quiet” period to accumulate PRM shares at this level cannot fail to see their investment multiply in value when the BIG news arrives in the New Year.............our CEO is reported to have valued PRM at over £12 per share – and that was before the implications of the grant of the TMT patents were fully appreciated..... Peter Snodgrass - 28 Dec'07 -....PRM is effectively backed by over £50 million cash.....It is one of the safest, most solid investments you are ever likely to find - far safer, for example, than many banks......the potential for the price to multiply, perhaps even in the next month or two, by five, ten or even twenty times is the best I have yet seen in my 70 years of investment experience. Peter Snodgrass - 31 Dec'07 - ....you should be warning the shorters that they are ALREADY in danger of going bankrupt.....That danger is real – and imminent....VIRxSYS.....PRM may get, any day now, the injection of around $1 billion cash (or assets of similar value) resulting from that takeover.....The promised TMT deal....will instantly turn PRM into a profitable company........TMT deal is expected to be followed by at least one comprehensive broker’s report which seems likely to confirm the CEO’s reported estimate that PRM is worth over £10 per share......The cash situation and consequently the share price, are just about to be transformed – greatly to the benefit of all LTHs. Peter Snodgrass - 31 Dec'07 -.....You, and others, appear not yet to have realised that the takeover price is now pretty certain to be over £8 per share - and probably within a couple of months. Peter Snodgrass - 2 Jan'08 - some "sensible posters" are too dim to understand the blindingly obvious.....shortly get proof of my theory via GE taking Intronn (either in cash or in part exchange) and handing back to PRM most of the rest of PRM's IP....will result, probably quite soon, in the true value (well over £8 - probably £12 - per share) of PRM becoming apparent - resulting in a takeover auction for PRM which I expect GE to win. Peter Snodgrass - 2 Jan'08 -.........356_tadpole - 19176 - "how long do you suppose it will take to get to £10 a share?" and "do you believe we could be waiting another five months for CJP to give us the news of a deal?"...........Possibly to £10 by later this month - if not then February at the latest....But it is the effect of the BIG deal (and one or more comprehensive brokers reports) that will cause the leap in the share price. Peter Snodgrass - 2 Jan'08 - .....I have published estimates of the true value of PRM's IP to be at least around £8 per share (which figure was also discussed back in early 2004 on this bb). Our CEO is reported to have estimated the value to be over £12 per share early last year and my research suggests that figure to now be conservative.....I have reason to believe that the true value of PRM will be disclosed when the TMT deal is announced (any day now) via a brokers circular and by the company. I expect these to show that the present price is utterly ridiculous.....in due course, but perhaps quite soon - there will be a takeover of PRM at a price nearer its true value. I have been wrong in my timing - but we now have a deadline that is unlikely not to be met. Peter Snodgrass - 3 Jan'08 - ........PRM will shortly be groomed for a takeover......I am convinced that any figure below £5 per share would be very strongly resisted by PRM and that a value in excess of £8 seems certain. The reported estimate (early last year) by our CEO of over £12 per fully diluted share seems more likely.....In consequence I believe that we are going to see the price multiply by over ten times........ Peter Snodgrass - 5 Jun'08 - ....as soon as PRM becomes profitable (which it probably is already but cannot yet announce it) then there will be a takeover bid at a large multiple of the present price.....likely to end up well in excess of £5 per share..... Peter Snodgrass - 7 Jan'08 - .....I now believe that part of GE Healthcare will be injected into PRM.... Peter Snodgrass - 19 Jan'08 - .....I expect, any day now, the announcement of the NEW agreement with GE which is going to startle most investors...... Peter Snodgrass - 19 Jan'08 - .....I have strong reasons for believing that the PRM value exceeds £8 per share.....I think that it probably exceeds £12 per share..... I expect an announcement of the TMT licence within days.....I expect an announcement (re GE) that will send the price towards £5 per share. ....any day now.....but.....not counting on it.....pretty certain that PRM will receive a takeover bid in excess of £8 per share (possibly £12 or more) within a couple of months...... Peter Snodgrass - 21 Jan'08 -.....I expect you to get proof, in the near future.....regarding GE's involvement with PRM.....Maybe even this week.... Peter Snodgrass - 21 Jan'08 - .....that method of investing enabled me to turn £32,000 into over £7 million in ten years. Yet none of the investments I used then had such great short term POTENTIAL as PRM obviously has now..... ....my research has convinced me that the demand for PRM’s IP will result in a takeover at a large multiple of the present price.... Peter Snodgrass - 26 Jan'08 - In the same way that PRM invited an auction for the TMT licence (merely to get a better price than GE were originally offering) so PRM itself is shortly going to advertise its value and invite a takeover auction for the company - which I expect GE to win - at a large multiple of the present price....I expect that VALUE (over £8 per share) to be publicised during the next few days - together with the TMT licence deal. Peter Snodgrass - 29 Jan'08 - Some shareholders seem to be expecting only the announcement of the TMT deal. But the new agreement with GE must also be announced.........I therefore expect a blockbuster announcement of the new GE/PRM agreement simultaneously with TMT and accompanied by a full blast of publicity – brokers’ reports, press releases, and media interviews.......That will reveal all the progress made in the last five years and result in an immediate enormous jump in the share price - way in excess of most investors’ current expectations from just the TMT deal....So - any day, any time, now.....few - if any - intending investors will be able to buy before the share price has rocketed to a multiple of its present level..... Peter Snodgrass - 30 Jan'08 - ....I expect the next PRM announcement to provide the proof that I have been right about the GE involvement all along........"Over £5" does not contradict £12 or £14. The actual statement attributed to our CEO was "£2 billion total value". In the context of that sentence "over £5" seemed more appropriate.... Peter Snodgrass - 24 Feb'08 - ...if the announcement of the TMT deal is followed (as I expect) by revelations about what has really been going on behind the scenes (and increasing the value of PRM) for the last four years, then the current price seems (IMO but DYOR) guaranteed to multiply by a greater factor than even the most optimistic shareholders expect.... Peter Snodgrass - 10 Mar'08 - ...It confirms my own view that the expected announcement (any day now?) of the TMT licence deal is likely to multiply PRM’s present price X3 almost instantly.... Peter Snodgrass - 24 Mar'08 - 13:38 - ....until we get details of the new agreement with GE we can only guess its contents. I expect it to be a temporary partnership (Option 1) to get the share price nearer to an agreed value (well over £5) - when PRM will probably then go to auction.......I expect the new agreement with GE to be announced with - or shortly after - the TMT licence deal. ......the Biofarmer suggestion (27121) of a takeover offer from ABI may liven things up! I think it would have to be way over £5 per share to be acceptable - even if GE bought the 43% Intronn separately.... Peter Snodgrass - 3 Apr'08 - ...freelance in his 28214 said that the Cubana investors " are confident of a 10 - 20 times increase on their investment.".....I also know that to be the case Peter Snodgrass - 13 Apr'08 - ....the announcement of that, including the sudden release of all the progress made over the last four years, that I expect to cause the giant leap in the share price..... Peter Snodgrass - 13 Apr'08 - Presumably because TF were a vastly better equipped company to extract maximum benefits worldwide in this field than GE Healthcare who otherwise would have been in competition with TF - which company GE probably has plans to take over. Peter Snodgrass - 21 May'08 - ....I later received information which leads me to believe that the planned publicising of the TMT deal alone may result, within a couple of weeks or so, in the share price approaching the 150p per share forecast in the Blue Oar Report dated 14 April....If the other information I listed (re Alzheimer's, HTS, etc etc) is also released then the share price should well exceed that Peter Snodgrass - 23 May'08 - ....That's fine. But what do you do when an announcement involving GE and - say - Intronn proves the old buffer to have been right and you have missed the chance to make X10 your money by not listening to him and following his line of thought? Peter Snodgrass - 26 May'08 - ....The bid will come from ABI,,,,,sooner rather than later - before, as roy123 says in 33002 - "TMT is about to EXPLODE into the market place!!" So - possibly this week? jeffian - 16 Apr 2012 - 18:35:55 - 14894 of 87785 Proteome Sciences leading Alzheimer's technology. - PRM Richard, I am not sure whether you are trying to delude yourself or the rest of us in persisting with the canard that you have never been wrong about anything to do with PRM other than "timing". The "timing" thing is a false device anyway as it simply defers indefinitely the moment when your prophecies are revealed as true or false (unless, like Minmet, the company concerned runs into a wall and the clock stops!). But you have certainly been wrong about some things (for example the values attributed in your 'guesstimates' to BSE/Biosite which appear to be dead ducks however long we wait) and you have been consistently wrong about the company's funding, stating in May 2003 that they had sufficient funds to last until cashflow positive (followed by the Placing in March 2005) and again in December 2006 (by which time CJP's loan facility was already in place) when you said that there was no need for any fundraising whatsoever which was followed by the Conversion, Placing and Open Offer of June 2010. Your "evidence-based" posts were often based on little evidence and a lot of extrapolation and in 11 years of following these boards I have yet to exclaim "Well, blow me down, old Richard was right all along!". Mind you, there's always time......
14/10/2020
16:51
tom barnaby: goatherd - 11 May'03 - 18:20 - 15315 of 33192 This is the 1st periodic update of my summary post [formerly 13824] My main assumption throughout this summary post is that proteomics is an entire new ballgame, capable of diagnosing diseases with unprecedented accuracy; and that Proteome has several years start on anyone else, and hence has a substantial number of patents thus making the barrier to entry of others very high. If the reader does not agree with this concept then doubtless they will not agree my figures. I have updated all test values; and altered the weight given to the various categories given in the next sentence. Proteome [or SP] say they have 14 tests licensed, ready to be licensed, or still being worked on. I think we can assume there will be more in due course. I have now posted on all except pain. For each condition [except sensitizer] I show the post number in which I posted my estimate and the expected gross royalty receivable in dollars once the test is fully in the market. When I made the individual estimates I made several caveats in each post. First was that I am assuming the test will be commercially successful – and perhaps all will not be. Then that I am a layman, that I have used no data except published information [though I have made deductions] and that while I only post in good faith I may of course be wrong, so it must be up to each individual to do their own research. Please note that I am not saying anything about timing. It could easily take five years to achieve these figures, or ten, or even more. In most, if not all, cases these tests are better than the existing alternative and cost less, probably with substantial savings to insurers or the NHS. Remember the health market is vast – and almost independent of boom or bust. I have indicated the source of the information – following an asterisk – *PRM is Proteome; *SP Seymour Pierce, *others spelt out. Already licensed :- assumed will achieve all of rated royalty Stroke PoC post #13,776 gross *SP at $265m, *SP 12% royalty $32m BSE, post #13,533 gross *PRM $490m, royalty *=Biosite? 12% $26m BSE, rest of world, #13,667, I estimated 3 times Europe $78m Total for already licensed - $136m Ready for commercialisation :- assumed will achieve two thirds of royalty Not actually a test– Sensitizer gross *Chataway £50m *FT 20% royalty £10m Stroke HTS post #13,776 gross *SP at $2,385m, *?same as PoC royalty $286m CJD in humans – small market for PoC; HTS will not be valuable unless a cure for CJD is found CJD blood HTS post 13,021, gross *goatherd $675m, *goatherd 12% royalty $81m Heart Transplant rejection post 12,414, gross *SP $52m, *goatherd 12% royalty $6m; this might extend to kidney transplants later Ischaemic/haemorrhagic stroke #15,315, gross *goatherd $67m, *goatherd 12% royalty $8m Total for ready for commercialisation - $391m two thirds is $260m ”working on”:- assumed will achieve one third of royalty Parkinson’s disease #15,294, gross *goatherd $5.75m, *goatherd 12% royalty $0.7m Pain – I have not been able to quantify this. Lung cancer #15,312, gross *goatherd $3150m *goatherd 15% royalty $472m Colon cancer, post #12,727, gross [assuming $20/test] *goatherd $1,640m, *goatherd 12%, royalty $200m Neuroblastoma #15,274 gross *goatherd $80m, *goatherd 12% royalty $9m. Breast cancer, #13,891m gross *goatherd $2,220m, *goatherd 12%, royalty $266m Pancreatic cancer #15,286. gross *goatherd $3000m, *goatherd 12% royalty $360m. Total for “working on” $1307m, one third is $435m The total royalties, reduced for stage above come to $832m or £518m I think one should assume 5% expenses in operating the patents and royalties; and tax at 30%. So the tax paid net earnings are £337m The value [once the markets are mature] can be determined by use of PE. This is determined by “feel” rather than rules, so I show the results of using PEs of 10, 15 and 17.92 – which is the current PE for pharma companies on the LSE [8/4/2003], and my preference. However take your pick! In all cases the total tax-paid net is £337m PE 10.0, market cap £3,370m share price £30 PE 15.0, market cap £5,055m share price £44 PE 17.9, market cap £6,039m share price £53 (edited) The other way of valuing is to look at dividends. Freelance in post 15293 of 10th May posted “The dividend issue is also very pertinent. The company told me about a month ago that they were projecting dividend payments within '2 to 3 years' as they had no intention of going on the acquisition trail and that they intend to keep the headcount low both in the UK and in Frankfurt.” Now if post-cash cash is £337, and the company follows the policy in the Freelance post then I would suggest the dividend would probably be covered 1.5 times. This gives a total dividend of £224m, for 114m shares, or £1.97 per share. The average yield on all shares on the LSE is 3.50%. If the same yield was to be available on Proteome the share price would need to be £56. Please note that these relate to the diagnostic tests [plus sensitizer] only. I intend to update all this at intervals, and I hope we will see the tests move gradually from “working on” to “ready for commercialisation221; to “licensed̶1;. Richard Dawson
14/10/2020
13:17
tom barnaby: Peter Snodgrass - 31 May 2013 - 09:08:52 - 31412 of 87751 Proteome Sciences leading Alzheimer's technology. - PRM Neudarian. Your 31385 and earlier post. I have not thought it necessary to post because, in spite of some of the nonsense appearing on this bb, the situation seems to me to be so clear (and in principle unchanged over recent years) that further comment was unnecessary. We have just had one of the most bullish (Preliminary) Annual Reports that I have ever seen published by any company. It also promises an important new deal “imminently221; – probably indicating that it has already been agreed and signed but its announcement delayed while the wording of that is agreed. As in any takeover situation the key issue is the VALUE of PRM’s IP to other companies – and that appears to be growing rapidly. Meanwhile, in PRM’s case particularly, the actual current earnings and financial state are utterly irrelevant. Furthermore, the less licensing deals completed and announced the greater will be the value to the company taking over PRM. The “imminent̶1; deal may however help the financial situation and thus the share price prior to any takeover. At some stage, and the AR suggests we are rapidly approaching it, a takeover auction will raise the price of PRM shares to a level which will astound many shareholders who have not done their homework. All the above seems obvious to me, and merely repeats – in principle - what I have been posting since January 2004 although unexpected events have delayed the timing. I think it is even possible that takeover talks are already (privately) taking place. Regards, Peter.
Proteome Sciences share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
PRM
Proteome S..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210414 07:49:46